CytoMed Therapeutics (GDTC): Aggregate Business Value

Brandmark of CytoMed Therapeutics Limited (GDTC)

This daily price chart on GURU.Markets for CytoMed Therapeutics (GDTC) shows a rate of 10.08. Strict regulatory oversight and patent law create a high barrier to entry in this sector. CytoMed Therapeutics (GDTC) aims for the global expansion of its platform for combating solid tumors. Additionally, the business relies on collaboration with clinics to develop personalized therapy regimens for gastrointestinal organs.

GDTC CytoMed Therapeutics: Enterprise Value in the range 11/23/2025 - 10/28/2026

GDTC (CytoMed Therapeutics Limited): analytical breakdowns and indicator data

- price and consensus price forecast:
Share Price CytoMed Therapeutics Ltd|GDTC - Consensus Target
- market capitalization data:
Market Value CytoMed Therapeutics|GDTC - Enterprise Value
- book capitalization data:
Accounting Value per Share CytoMed Therapeutics|GDTC - Book Capitalization|Market Cap to Net Assets Ratio w2.cytomed.sg|GDTC - Company Total Assets
- debt and liquidity data:
Total Debt to Capital CytoMed Therapeutics|GDTC - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio CytoMed Therapeutics Ltd|GDTC - Company Aggregate Debts|Debt to Book Value CytoMed Therapeutics|GDTC - Company Long-Term Debts|Short-Term Debt CytoMed Therapeutics
Fundamental company valuation:GDTC (CytoMed Therapeutics)
Manufactured products of CytoMed Therapeutics

Fundamental analysis requires separating market noise from the actual value of a business. This indicator sums market capitalization and net debt to determine the total acquisition price of an asset. By analyzing the company's valuation via the EV metric, an investor sees the actual cost of buying out the enterprise. For CytoMed Therapeutics (GDTC), this figure reflects the value of innovations in cell therapy. Outsourcing clinical trials minimizes capital expenditures, stabilizing the balance sheet and the overall enterprise value.

Direct competitors

ONC - Business Value|Real Price to Acquire Entire Company Halozyme Inc. HALO|RVMD - Aggregate Business Value|AAPG (Ascentage Pharma Group) - Enterprise Value|cgoncology.com (CGON) - Real Price to Acquire Entire Company|Enterprise Value URGN|Real Price to Acquire Entire Company Bicara Therapeutics Inc|Enterprise Value PSNL|Enterprise Value ERAS (Erasca Oncology)|DCTH - Total Company Value|Business Value ymabs.com YMAB|AURA: Enterprise Value|CADL - Real Price to Acquire Entire Company|Enterprise Value ARAY|SLS (SELLAS Life Sciences Group) - Total Enterprise Value|ACTU - Total Company Value|Value Adjusted for Debt and Cash citiusonc.com (CTOR)|TuHURA Biosciences, Inc. (HURA) - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash Protara Therapeutics Inc (TARA)|Fate Therapeutics Corp - Enterprise Value|WHWK - Real Price to Acquire Entire Company|TScan - Real Price to Acquire Entire Company|CSBR: Enterprise Value|Total Company Value xbiotech.com XBIT|CEL-SCI (CVM) - Value Adjusted for Debt and Cash|Enterprise Value OSTX (OS Therapies Inc)|Total Enterprise Value radiopharmtheranostics.com|Enterprise Value ARTV (Artiva Biotherapeutics, Inc.)|Real Price to Acquire Entire Company adlainortye.com ANL|VERU: Real Price to Acquire Entire Company|TPST - Total Enterprise Value|Real Price to Acquire Entire Company Xilio XLO|RENB: Aggregate Business Value|Total Company Value MURA|KAPA (Kairos Pharma) - Total Enterprise Value|Total Company Value OKUR|Real Price to Acquire Entire Company Curis Corp|Apollomics, Inc. - Enterprise Value|Total Enterprise Value Tharimmune Corporation (THAR)|ADVB - Enterprise Value|GNPX - Business Value|Real Price to Acquire Entire Company Calidi Bio (CLDI)|sunshinebiopharma.com (SBFM) - Value Adjusted for Debt and Cash|XBIO - Real Price to Acquire Entire Company|Salarius Pharma (SLRX) - Aggregate Business Value|PPBT - Enterprise Value|Value Adjusted for Debt and Cash AON|BeiGene - Enterprise Value|Total Enterprise Value CKPT (Checkpoint Therapeutics Inc.)|Total Company Value Elevation Oncology|Value Adjusted for Debt and Cash iCAD Inc. ICAD|Ikena - Enterprise Value|NTBL: Enterprise Value|Total Company Value viracta.com (VIRX)|MorphoSys Inc (MOR) - Full Business Value|Enterprise Value NAYA (NAYA Bio)|Total Enterprise Value Ascentage (AAPGV)